Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02960763
Other study ID # 201609085
Secondary ID TRD-1511-33321
Status Completed
Phase Phase 4
First received
Last updated
Start date February 24, 2017
Est. completion date September 1, 2021

Study information

Verified date November 2022
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).


Description:

Older adult participants with treatment-resistant depression will be randomly assigned to a Step 1 medication strategy. - Adding aripiprazole to current antidepressant medication - Adding bupropion to current antidepressant medication - Replacing current antidepressant medication with bupropion If depression is not relieved at the end of 10 weeks, or if participants do not qualify for Step 1, participants will be randomly assigned to a Step 2 medication strategy: - Adding lithium to current antidepressant medication - Replacing current antidepressant medication with nortriptyline All medication strategies will be offered in collaboration with participants' own physicians with the the research team providing support and guidance. After treatment in Step 1 and/or Step 2, participants will enter the Continuation Phase to assess long term follow-up outcomes for 12 months. Participants in this clinical trial will also be asked to participate in an additional study to gather imaging and biomarker data.


Recruitment information / eligibility

Status Completed
Enrollment 742
Est. completion date September 1, 2021
Est. primary completion date September 28, 2020
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Men and women aged 60 and older - Current Major Depressive Disorder (MDD) - Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length - Patient Health Questionnaire-9 (PHQ-9) score of 10 or higher Exclusion Criteria: - Inability to provide informed consent - Dementia - Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms - High risk for suicide and unable to be managed safely in the clinical trial - Contraindication to proposed study medications, as determined by study physician including history of intolerance or non-response to proposed medications. - Non-correctable, clinically significant sensory impairment interfering with participation - Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management. - Moderate to severe substance or alcohol use disorder

Study Design


Intervention

Drug:
Aripiprazole Augmentation
Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
Bupropion Augmentation
Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
Switch to bupropion
Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
Lithium Augmentation
Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
Switch to nortriptyline
Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml

Locations

Country Name City State
Canada Centre for Addiction and Mental Health Toronto Ontario
United States UCLA Late-Life Mood, Stress, and Wellness Research Program Los Angeles California
United States Columbia University Adult and Late Life Depression Clinic New York New York
United States UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program Pittsburgh Pennsylvania
United States Washington University School of Medicine Healthy Mind Lab Saint Louis Missouri

Sponsors (3)

Lead Sponsor Collaborator
Washington University School of Medicine National Institute of Mental Health (NIMH), Patient-Centered Outcomes Research Institute

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Psychological Well-Being Psychological well-being was assessed using the NIH Toolbox Psychological Wellbeing subscales of Positive Affect and General Life Satisfaction, with a T score calculated as the average of these two subscales. Higher scores indicate greater positive affect and life satisfaction. Reference T-score (mean=50, SD=10). Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks
Primary Number of Participants With Remission From Depression Remission defined as Montgomery Asberg Depression Rating Scale score =10. Scale ranges from 0-60 with higher scores indicating higher depressive symptoms. Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks
Primary Serious Adverse Events Life threatening illness, hospitalization, or need of medical care. Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A